Cognitive deficits as long-term side-effects of adjuvant therapy in breast cancer patients: 'Subjective' complaints and 'objective' neuropsychological test results

Psycho-Oncology

Volumn 18, Issue 7, 2009, Pages 775-782

  Weis, J ^a   Poppelreuter, M ^a   Bartsch, H H ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Breast cancer; Long term treatment effects; Neuropsychological outcome; Neurotoxicity; Oncology; Systematic therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; COGNITIVE DEFECT; COGNITIVE REHABILITATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NEUROPSYCHOLOGICAL TEST; PREVALENCE; SELF EVALUATION; SEMANTIC MEMORY; VERBAL MEMORY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PERSONALITY INVENTORY; PSYCHOMETRICS; SELF CONCEPT; SICK ROLE;

EID: 67749131036     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.1472     Document Type: Article

References (30)

1. Ganz PA, Desmond KA, Leedham B et al. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 2002;94:39-49.
2. Ahles TA, Saykin AJ, Furstenberg CT et al. Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. J Clin Oncol 2005; 23:4399-4405. DOI: 10.1200/JCO.2005.03.343.
3. Faletti MG, Sanfilippo A, Maru. P et al. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 2005;59:60-70. DOI: 10.1016/j.bandc.2005.05.001.
4. Stewart A, Bielajew C, Collins B et al. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 2006;2:76-89. DOI: 10.1080/138540491005875.
5. Vardy J, Rourke S, Tannock IF. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 2007; 25:2455-2463. DOI: 10.1200/JCO.2006.08.1604.
6. Vardy J, Wefel, JS, Ahles T et al. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol, Advance Access published online October 31, 2007 (latest access 22.11.2007). DOI: 10.1093/annonc/mdm500.
7. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007;7:192-201. DOI: 10.1038/ nrc2073.
8. Jenkins V, Shilling V, Fallowfield L et al. Does hormone therapy for the treatment of breast cancer have a detrimental e.ect on memory and cognition? A pilot study. Psycho-Oncology 2004; 13:61-66. DOI: 10.1002/pon.709.
9. Bender CM, Sereika SM, Berga SL et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology 2006;15:422-430. DOI: 10.1002/pon.964.
10. Hurricane Voices. Cognitive changes related to cancer treatment. Published online 2007. www.hurricanevoices. org/today/cognition/ index.htm; www.hurricanevoices.org/today/cognition/ hv_cognitive_results.pdf (latest access 28.09.2007).
11. Cull A, Hay C, Love SB et al. What do cancer patients mean when they complain of concentration and memory problems? Br J Cancer 1996;74:1674-1679.
12. Weis J, Bartsch HH, Nagel GA, Unger C. Psychosocial care for cancer patients: a new holistic psychosomatic approach in acute care and rehabilitation. Psycho-Oncology 1996;5:51-54.
13. Weis J, Moser MT, Bartsch HH. Goal-oriented evaluation of inpatient rehabilitation programs for women with breast cancer (ZESOR-Study). In Jäckel W, Bengel J, Herdt J (eds). Research in Rehabilitation: Results of a Research Network in Southwest Germany. Thieme: Stuttgart, Germany, 2006;162-171.
14. Poppelreuter M, Weis J, Bartsch HH. Effects of specific neuropsychological training programs for breast cancer patients after adjuvant chemotherapy. J Psychosoc Oncol, under revision.
15. Zimmermann P, Fimm B. Testbatterie zur Aufmerksamkeitsprüfung (TAP; Version 1.7). Psytest: Würselen, Germany, 2001.
16. Aaronson NK, Ahmedzai S, Bergman B et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
17. Smets EMA, Garssen B, Bonke B et al. The Multidimensional Fatigue Inventory (MFI). Psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-325.
18. Herrmann CH, Buss U, Snaith RP. Hospital Anxiety and Depression Scale - Deutsche Version (HADS-D). Hans Huber: Bern, Switzerland, 1995.
19. Zimmermann P, Messner C, Poser U et al. Ein Fragebogen erlebter Defizite der Aufmerksamkeit (FEDA). Unpublished manuscript: University of Freiburg: Germany, 1991.
20. Sturm W. Aufmerksamkeitsstörungen. Hogrefe: Göttingen, Germany 2005.
21. Wilson BA, Cockburn J, Baddeley AD. Rivermead Behavioral Memory Test. Bury St Edmunds, Great Britain: Thames Valley Test Company 1985. (German adaption: Beckers K, Behrends U, Canavan A. Düsseldorf, Germany: Neurologisches Therapie Centrum 1992.)
22. Wechsler D. Wechsler Memory Scale - Revised Form (WMS-R). San Antonio, TX: The Psychological Corporation 1987. (German adaption: Härting C, Markowitsch HJ, Neufeld H et al. Bern, Switzerland: Huber 2000.)
23. Bäumler G. Der Lern- und Gedächtnistest LGT-3. Hogrefe: Göttingen, Germany, 1974.
24. Poppelreuter M, Weis J, Külz AK et al. Cognitive dysfunction and subjective complaints of cancer patients: a cross sectional study in a cancer rehabilitation center. Eur J Cancer 2004;40:43-49. DOI: 10.1016/j.ejca.2003.08.001.
25. Sturm W, Willmes K, Orgass B, Hartje W. Do specific attention deficits need specific training? Neuropsychol Rehab 1997;7:81-103.
26. Wefel JS, Lenzi R, Theriault RL et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Results of a prospective, randomized, longitudinal trial. Cancer 2004;100: 2292-2299. DOI: 10.1002/cncr.20272.
27. Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 2001;37: 1245-1351.
28. Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 2007;11:6-15. DOI:10.1016/j.ejon.2006.02.005.
29. Stewart A, Collins B, Mackenzie J et al. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psycho-Oncology 2008;17:122-130. DOI: 10.1002/pon.1210.
30. Shilling V, Jenkins V, Fallowfield L, Howell A. The effects of oestrogens and anti-oestrogens on cognition. Breast J 2001; 10:484-491. DOI: 10.1054/brst.2001.0311.